Indolent non-Hodgkin lymphoma
Clinical trials for Indolent non-Hodgkin lymphoma explained in plain language.
Never miss a new study
Get alerted when new Indolent non-Hodgkin lymphoma trials appear
Sign up with your email to follow new studies for Indolent non-Hodgkin lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise for Hard-to-Treat lymphomas
Disease control Stopped earlyThis study tested a combination of two drugs, favezelimab and pembrolizumab, in 137 people with certain blood cancers like Hodgkin lymphoma and B-cell lymphoma. The goal was to see if the combination was safe and could shrink tumors. The study also looked at each drug alone in so…
Matched conditions: INDOLENT NON-HODGKIN LYMPHOMA
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Experimental cell therapy for tough blood cancers put on hold
Disease control Stopped earlyThis early-stage study tested a new treatment called CNTY-101 for people with B-cell cancers that came back or didn't respond to other therapies. The main goals were to find a safe dose and see if the treatment could shrink tumors. The study was stopped early, so results are limi…
Matched conditions: INDOLENT NON-HODGKIN LYMPHOMA
Phase 1 • Sponsor: Century Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Drug combo aims to control Slow-Growing lymphoma without chemo
Disease control Stopped earlyThis phase 2 study tested a combination of two drugs, lenalidomide and rituximab, in 30 people with previously untreated indolent non-Hodgkin's lymphoma. The goal was to see how well the drugs worked together to shrink or control the cancer. Participants took lenalidomide daily f…
Matched conditions: INDOLENT NON-HODGKIN LYMPHOMA
Phase 2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC